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Case presentation
A 67-year-old black man was admitted to the West Side Veterans
Administration Hospital in Chicago because of weakness and clinical
signs of volume contraction. He gave no history of vomiting, diarrhea,
diuretic use, or any other obvious cause of volume depletion. Physical
examination revealed an afebrile thin man with decreased skin turgor.
His blood pressure, 100/80 mm Hg in the supine position, fell to 90/70
mm Hg on standing. Ophthalmic examination revealed early cataracts.
The remainder of the physical examination was unremarkable. The
patient had a history of chronic congestive heart failure, sickle-cell trait,
mild renal insufficiency, chronic normochromic normocytic anemia,
and recurrent urinary tract infections. A plain chest x-ray film showed
cardiomegaly. An electrocardiogram was consistent with an old myo-
cardial infarction but was otherwise unremarkable. An intravenous
pyelogram performed several months previously showed distortion of
the calyceal system in the right kidney without evidence of hydrone-
phrosis or papillary necrosis. On admission, the BUN was 76 mg/dl; it
decreased to 33 mg/dl after 2 days of fluid replacement with normal
saline. In response to this treatment, his plasma sodium and total
protein levels also fell from 150 to 135 mEq/liter and from 7.9 to 6.0 g/dl,
respectively. Plasma potassium, measured at 7.0 mEq/liter, fell to 4.8
mEq/liter after hydration and administration of sodium polystyrene
sulfonate.
After 2 weeks, the plasma potassium again rose to 7.0 mEq/liter, and
a renal consultation was requested. At that time, the BUN was 56 mg/
dl; plasma creatinine, 2.5 mg/dl; plasma sodium, 140 mEq/liter; chlo-
ride, 112 mEq/liter; and total CO2, 17 mmol/liter; arterial blood pH was
7.32; PaCO2, 33 mm Hg; and Pa02, 82 mm Hg. Urine electrolytes were:
sodium, 101 mEq/liter; potassium, 7 mEq/liter; and chloride, 66 mEq/
liter. Urinalysis showed 5 to 10 red blood cells per high-power field. A
24-hour urine collection contained no protein; the endogenous creati-
nine clearance was 35 mI/mm. After spontaneous voiding, the urine
volume recovered by bladder catheterization was less than 20 ml.
Following normal saline infusion for several days, plasma renin activity
was 1.2 ng/ml/hr; plasma aldosterone, 0.9 ng/dl; and plasma potassium,
5.5 mEq/liter. After furosemide administration (40 mg orally at 6 P.M.,
12 midnight, and 6 AM,), the plasma renin activity was 7.2 ng/ml/hr,
plasma aldosterone was 3.8 ng/dl, and plasma potassium was 5.1 mEq/
liter.
In the presence of spontaneous metabolic acidosis (venous blood pH,
7.28; PCO2, 43 mm Hg; and total C02, 19 mmol/liter), urine pH was
5.89. Ammonium excretion was 3.8 smol/min; titratable acid excretion,
8.5 mol/min; and net acid excretion, 12 jsmol/min. Intravenous
administration of sodium sulfate had no effect on urine pH (from 5.92 to
5.93) or potassium excretion (from 43 to 42 mol/min), whereas sodium
excretion increased from 25 to 110 smol/min. Administration of aceta-
zolamide also had little effect on potassium excretion as shown by a
subnormal increase in fractional potassium excretion (from 10% to
14.5%). Renal sodium handling was examined while the patient ingested
a low-salt diet for 14 days. During this time, the patient was given 0.1
mg of fludrocortisone daily. On the 10th day of a diet containing 40 mEq
of sodium and 60 mEq of potassium, sodium and potassium excretion
exceeded and fell below intake by 52 and 19 mEq per 24 hours,
respectively. After 4 additional days of a diet containing 10 mEq of
sodium, the 24-hour sodium excretion fell to 23 mEq, a value still
greater than the dietary intake. Plasma potassium ranged from 6.1 to 6.6
mEq/liter throughout the 14 days of observation. Dietary sodium
restriction was terminated on the 14th day because the patient had lost
1.6 kg in weight and had developed a postural change in blood pressure
and pulse.
Discussion
DR. NEIL A. KURTZMAN (Professor of Medicine and Physiol-
ogy, and Chief, Section of Nephrology, University of Illinois
College of Medicine, Chicago, Illinois): Although described
earlier [1, 2], distal renal tubular acidosis was first put in
perspective by Aibright, Burnett, and Parson in 1946 [3]. They
described a syndrome consisting of hypokalemia, hyperchlore-
mic metabolic acidosis, inability to lower the urine pH below
5.5, nephrocalcinosis, and nephrolithiasis; additional features
included osteomalacia or rickets. Because the establishment of
a large pH gradient between urine and blood is a function of the
distal nephron, the syndrome was named distal renal tubular
acidosis (DRTA).
Until recently, DRTA was considered to have a single
pathogenesis. The prevailing view was that the disorder result-
ed from an inability to generate or maintain a steep hydrogen
ion gradient across the distal nephron rather than from failure to
secrete protons. This hypothesis was based on the observation
that maximal reabsorptive capacity for bicarbonate during
Presentation of the Forum is made possible by grants from Smith Kline
& French Laboratories, CIBA Pharmaceutical Company, and GEIGY
Pharmaceuticals.
807
© 1983 by the International Society of Nephrology
Editors
JORDAN J. COHEN
JOHN 1. FIARRINGTON
JEROME P. KASSIRER
NICOLAOS E. MADJAS
Managing Editor
CHERYL J. ZUSMAN
Michael Reese Hospital and Medical Ceizier
University qi Chicago Pritzker School of Medicine
and
New England Medical Center
Tufts Univç,-sj School of Medicine
808 Nephrology Forum
bicarbonate loading is either normal or increased in patients
with this syndrome [4]. Because hydrogen ion secretion is
thought to be the mechanism responsible for bicarbonate reab-
sorption, Seldin and Wilson reasoned that hydrogen ion secre-
tion in the distal nephron was intact [4]. The observation by
Reynolds [5] that titratable acid excretion in patients with
DRTA increased during sodium phosphate administration also
suggested intact distal proton secretory capacity.
For these and other reasons, Seldin and Wilson proposed that
the failure of patients with DRTA to lower urine pH during
acidemia did not result from a failure in distal proton secretion,
but rather was the consequence of an inability to generate or
maintain a steep pH gradient across the distal nephron. Accord-
ingly, DRTA often was referred to as "gradient" RTA. More
recently, the expansion of our knowledge concerning the con-
trol of distal urinary acidification and the development of a
number of experimental models of DRTA have enlarged and
modified our understanding of the pathogenesis of this syn-
drome. I plan to discuss the mechanisms and evaluation of urine
acidification in some detail, emphasizing this newer information
before turning to a discussion of the clinical features of DRTA.
Acidification of urine
Acidification occurs in two general segments of the nephron.
The proximal tubule is responsible for the reabsorption of the
great bulk of filtered bicarbonate. More than 90% of the
absorbed bicarbonate is transported in this segment. Under
ordinary conditions, the distal tubule and collecting duct re-
claim the remaining 10% of the filtered bicarbonate, lower the
urine pH to its final value, and titrate most of the nonbicarbon-
ate urinary buffers. Although the proximal tubule and distal
nephron overlap with respect to their acidification functions, as
an approximation the proximal tubule can be considered as the
site of bicarbonate reclamation, and the distal nephron the site
of acid excretion. In the distal nephron (mainly the collecting
duct), hydrogen ion secretion titrates the two main urinary
buffers, phosphate and ammonia, and results in the excretion of
acid in the form of titratable acid and ammonium. Acidification
in the cortical collecting tubule is indirectly coupled to sodium
transport and is influenced by transepithelial voltage [6]. Active
sodium reabsorption in this nephron segment generates a nega-
tive electrical potential within the lumen that favors the active
secretion of protons. Acidification in the medullary collecting
tubule is not influenced by sodium transport and occurs against
an electrical gradient [6, 71. The potential difference in this
nephron segment is oriented lumen positive, most likely the
result of active proton secretion. The magnitude of proton
secretion is greater in the medullary than in the cortical segment
of the collecting tubule.
Evaluation of distal acidification
Minimal urine pH during metabolic acidosis
Measurement of the urine pH is the first step in assessing the
integrity of distal urinary acidification. When systemic pH is
below 7.35, the urine pH is usually less than 5.5 in normal
individuals. Finding the urine pH below 5.5 suggests, but does
not prove, that acidification mechanisms are intact. For exam-
ple, a urine pH below 5.5 can be found in patients with distal
RTA due to selective aldosterone deficiency. Moreover, a urine
pH below 5.5 can be found in patients with proximal RTA in
whom the plasma bicarbonate concentration has fallen to values
below the decreased "threshold" for bicarbonate reclamation
in the proximal tubule [8—101.
The urine pH should be measured on freshly voided urine
obtained in the morning and collected under mineral oil to
prevent the loss of carbon dioxide. If the patient is acidemic,
there is no need to perform an ammonium chloride loading test
because mild acidemia should be sufficient to provoke a maxi-
mal decline in urine pH. Urine pH can be influenced by the
patient's position and by the rate of urine flow. Since the
recumbent position can increase pH [111, the patient should
void, if possible, in the upright position. If systemic acidemia is
not present, ammonium chloride should be given orally in a
dose of 0.1 glkg daily for 3 to 5 days [11]. Alternatively, a single
dose may be given and the urine collected hourly over the next
2 to 8 hours. We prefer the 3-day test because it seems to give
more reliable results and allows time for a maximal increase in
ammoniurn excretion [12, 13]. The urine pH in normal subjects
falls below 5.5 (usually below 5.0) by the first day and remains
below 5.5 for the duration of the test. Ammonium excretion
normally increases at least threefold by the third day of
ammonium chloride administration [13].
The finding of a urinary pH above 5.5 in the presence of
systemic acidemia and in the absence of urinary tract infection
strongly suggests the diagnosis of DRTA. Patients with salt-
retaining diseases may respond abnormally to acidemia owing
to inadequate distal delivery of sodium even though distal
acidification is intact, An adequate history and the measure-
ment of sodium concentration in the collected urine can elimi-
nate this possibility. There are a few patients, however, in
whom urine pH can fall below 5.5 even though there is a defect
in distal acidification [13, 14]. Evidence of such a defect can be
disclosed by measuring the urine PCO2 during bicarbonate
loading, as I will discuss later.
Excreted acid appears in the urine either as titratable acidity
or ammonium. Because acid excretion when corrected for GFR
does not fall in renal insufficiency—indeed it may rise—and
because many patients with impaired distal acidification have
renal insufficiency, it is important to compare net acid excretion
(titratable acid + ammonium — bicarbonate) during an ammoni-
urn chloride loading test or during spontaneous acidemia with
values obtained from controls having similar GFRs.
Calcium chloride is an alternative acidifying agent that can be
used in patients who cannot tolerate ammonium chloride or in
whom its use is contraindicated (for example, patients with liver
insufficiency) [14]. This compound is given in a dose of 2 mEqi
kg orally. It results in an acidification response almost identical
to that observed following the administration of ammoniuni
chloride.
Urine PCO2 as an index of distal acidification
Urine PCO2 during sodium bicarbonate infusion. After alka
linization of the urine produced by systemic sodium bicarbon
ate infusion, the urine PCO2 reaches a value considerably above
that of blood [12, 13, 15—17]. Normally the urine PCO2 rise
above 70 mm Hg after maximal alkalinization of the urine (pF
7.8 or greater) provided that the urine bicarbonate concentra
tion exceeds 80 mEq/liter. Although the factors controlling the
generation of urinary PCO2 are still not completely elucidated
hydrogen ion secretion is considered responsible for a majo
component of the increase [13, 15].
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Because the urine PCO2 exceeds that of blood under condi-
tions of bicarbonate loading, and because the PCO2 of intrare-
nal blood was assumed to be equal to that of systemic blood, the
term U-B PCO2 gradient came into vogue. This value is
obtained by subtracting the value for the PCO2 of systemic
blood from that of urine. The observation that U-B PCO2 was
lower in subjects with DRTA than in normal individuals
strengthened the view that this index was a useful measure of
distal urinary acidification [15].
There are several caveats that must be observed in the use of
the U-B PCO2 gradient to assess urine acidification. First, as I
mentioned, the urine must be maximally alkaline and contain
bicarbonate in high concentration. Second, we now know that
the PCO2 of intrarenal blood varies considerably from that of
systemic blood 118—211. Furthermore, because carbon dioxide
is diffusible and because the PCO2 of intrarenal blood approxi-
mates that of intratubular urine at the same level in both
proximal and distal nephron, there is little reason to believe that
carbon dioxide gradients exist across the tubule [18, 211. Thus a
more proper and more direct measure of urinary acidification is
likely the urine PCO2 itself rather than the U-B PCO2 gradient
[22]. Under conditions in which the blood PCO2 remains
unchanged, an examination of the U-B PCO2 gradient is essen-
tially the same as examining the urine PCO2. When blood PCO2
changes, however, use of the gradient may produce erroneous
conclusions owing to the presence of two variables. For exam-
ple, using the U-B PCO2 gradient as an index of distal acidifica-
tion recently led to the conclusion that acute hypercapnia
inhibits distal urinary acidification [23]. The oppposite conclu-
sion would have been reached had urine PCO2 been used as the
index of distal acidification.
The rationale for using the urine PCO2 as an index of
acidification is that secretion of a proton into urine containing
bicarbonate results in the generation of carbonic acid which, in
turn, produces carbon dioxide. The more the hydrogen ion
secretion, the higher the urine PCO2. The test is performed by
infusing a 1 M solution of sodium bicarbonate at a rate of 3 ml!
mm into a peripheral vein. Timed urine collections over approx-
imately 15 to 30 minutes are obtained by spontaneous voiding in
the upright position. Urine should be collected under mineral oil
for measurement of urine pH and urine PCO2. Bicarbonate
concentration is calculated using the Henderson-Hasselbaich
equation correcting the pK' for ionic strength. Venous blood
samples are obtained at the midpoint of every other urine
collection for determination of pH and PCO2. The test is
terminated after the pH of at least three consecutive urine
collections is above 7.8. An infusion lasting approximately 180
to 260 minutes is usually required. A convenient way of
visualizing the results is to plot urine PCO2 against urine
bicarbonate concentration.
Urine PCO2 during neutral sodium phosphate infusion. A
critical dependency of urine PCO2 on urinary phosphate con-
centration exists when the pH of urine is close to the pK' of a
phosphate buffer system (that is, 6.8) [24—27]. In a highly
alkaline urine (pH greater than 7.8), phosphate concentration
plays no role in the generation of urine PCO2, because almost
all the phosphate is in its alkaline form and incapable of
donating a proton that could titrate bicarbonate to carbon
dioxide [24—26]. At a urine pH of about 6.8, however, the urine
bicarbonate concentration is sufficient to generate carbonic acid
and carbon dioxide provided acidification is stimulated, but the
urine bicarbonate concentration per se plays no role in the
kidney's ability to generate a high urine PCO2 as it does during
bicarbonate loading. At this pH, half the phosphate is in its acid
form and thus is capable of titrating bicarbonate to carbon
dioxide.
The test is performed by infusing neutral phosphate (1 mmol/
liter total body water dissolved in 180 ml of normal saline) at a
rate of 1 ml/min for 3 hours. This procedure usually results in a
two- to threefold increase in plasma phosphate concentration
[12, 13, 25, 26]. Urine phosphate concentration must increase to
at least 20 mmol/liter in 2 to 3 successive collections after the
beginning of the phosphate infusion. Under these conditions,
urine PCO2 is consistently 25 mm Hg above that of blood, both
in normal individuals and in patients with renal insufficiency
[12, 13, 25, 26].
We have used the response of urinary PCO2 to phosphate
infusion to determine the mechanisms responsible for impaired
distal acidification in DRTA [28]. We reasoned that if DRTA is
the result of impaired distal proton secretion, the urine PCO2
should not increase normally in response to either bicarbonate
or neutral phosphate loading. If, on the other hand, the cause of
DRTA were a back-leak of acid, then the response of urine
PCO2 to phosphate administration might be normal, whereas
the response to bicarbonate infusion would be decreased. We
reasoned as follows: If proton secretion were intact but the
ability to maintain a gradient were reduced, then phosphate
administration would stimulate proton secretion and cause the
secreted hydrogen ion to form acid phosphate, a moiety that is
much less diffusible than the carbonic acid formed during
titration of bicarbonate. The reaction of acid phosphate with
bicarbonate to form carbonic acid and carbon dioxide would be
delayed and would occur at a location in the nephron or urinary
tract where back diffusion could not take place. Thus, theoreti-
cally at least, a back-leak defect might respond normally to
neutral phosphate administration. It should be mentioned that
there are distal acidification defects in which the urine PCO2
does not rise normally during bicarbonate infusion but does
respond appropriately to phosphate administration; I will talk
about these later [12, 13, 24]. Thus, phosphate infusion is a
stronger stimulus to the generation of carbon dioxide than is
bicarbonate.
Sodium sulfate infusion
Normal subjects lower the urine pH below 5.5 provided distal
sodium delivery is adequate and sodium reabsorption is avid.
The latter requirement can be accomplished by administering 9-
Iludrohydrocortisone, 1 mg orally, 12 hours before the sodium
sulfate test is performed. The first requirement is achieved by
the acute administration of the salt of a poorly reabsorbable ion
such as sodium sulfate. Sodium sulfate stimulates acidification
by increasing negative voltage in the cortical collecting tubule
[25, 26, 29—31]. A properly performed sodium sulfate test yields
a fall in urine pH below 5.5 (usually 5.0) whether or not
systemic acidosis is present. Urine collections should be contin-
ued for 2 to 3 hours after the end of the sodium sulfate infusion,
because some subjects have a delayed response. Typically 500
ml of a 4% solution of sodium sulfate is infused over a 45- to 60-
minute period. In addition to a fall in urine pH below 5.5,
sodium sulfate infusion induces a marked increase in potassium
and ammonium excretion. The sodium sulfate test provides the
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same information as that obtained by infusion of sodium neutral
phosphate. We have yet to observe a subject who responded
differently to the two procedures.
Bicarbonate reabsorption
Because patients with DRTA have intact proximal acidifica-
tion, and because the measurement of maximal bicarbonate
reabsorptive capacity during bicarbonate loading is mainly a
function of proximal acidification, the "Tm" for bicarbonate
reabsorption in these patients is not reduced [4]. In fact, it tends
to be somewhat increased. This increase probably results from
some degree of volume contraction commonly found in these
subjects along with their chronic acidemia. Acidemia can
stimulate proximal acidification by increasing intracellular pH.
Because patients with DRTA cannot lower urine pH below 5.5,
and usually not below 6.0, small amounts of bicarbonate are
always present in the urine. Thus, a characteristic small leak of
bicarbonate is seen during the performance of a bicarbonate
titration curve in these patients when the plasma bicarbonate is
less than normal. This response contrasts with the bicarbonate-
free urine normally elaborated under such circumstances. It is
rarely necessary to perform a full titration experiment. A
proximal defect in acidification can effectively be excluded by
demonstrating a fractional excretion of bicarbonate below 5%
when the plasma bicarbonate is above 20 mEq/liter [10, 32].
Experimental defects in urinary acidification
Experimentally, three main defects in distal acidification
have been identified. The defects are due to an inability to
generate a negative potential difference in the collecting duct (a
voltage-dependent defect), to a back-leak of acid, or to aldoster-
one deficiency.
Voltage-dependent defects
Urinary tract obstruction, We studied urinary acidification in
dogs with unilateral ureteral obstruction [32]. One ureter was
ligated for 24 hours. The ligature was then removed and the
ureters from the postobstructed kidney and the normal kidney
were cannulated. Bicarbonate was infused and the U-B PCO2
gradient measured. These studies showed that the ability to
raise the urine PCO2 (at any given urine bicarbonate concentra-
tion) was lost by the postobstructed kidney. The normal kidney,
by contrast, exhibited the typical increase in U-B PCO2 gradi-
ent just described for bicarbonate loading. The postobstructed
kidney also demonstrated reduced potassium excretion during
bicarbonate loading.
To further characterize this disorder, we studied the ability to
raise urine PCO2 during phosphate administration. When phos-
phate was administered to animals with unilateral ureteral
obstruction, urine PCO2 rose normally in the nonobstructed
kidney but failed to change appreciably in the urine obtained
from the postobstructed kidney.
We also studied the effect of sodium sulfate infusion in these
animals. Sodium sulfate, unlike phosphate, is not a buffer; it
exerts its acidifying response through a voltage-dependent
mechanism. Because the sulfate ion is nonreabsorbable, the
reabsorption of sodium in the cortical collecting tubule unac-
companied by sulfate generates a highly negative electrical
potential within the lumen, favoring secretion of protons and
potassium. Thus, in addition to acidifying the urine, sodium
sulfate infusion results in kaliuresis. Again, the postobstructed
kidney responded in a markedly abnormal fashion [33]. Urine
Table 1. Effects of urinary obstruction and amiloride on urinary
function
Urinary
obstruction Amiloride
Ability to lower
urine pH Decreased Decreased
U-B PCO2 in
alkaline urine Decreased Decreased
U-B PCO2 with
phosphate infusion Decreased Decreased
Urinary acidification
following sulfate
infusion Decreased Decreased
Sodium excretion Increased Increased
Potassium excretion Decreased Decreased
pH fell only to about 6.5, and the increment in ammonium
excretion was markedly attenuated. Furthermore, compared to
the normal kidney, significantly less potassium was excreted.
The final study performed in these animals was desoxycortico-
sterone acetate administration. This mineralocorticoid de-
creases urinary sodium excretion by acting at the cortical
collecting tubule [34]. The postobstructed kidney was markedly
resistant to the sodium-retaining effects of this agent. Thus, this
study demonstrated defects in urinary acidification, sodium
reabsorption, and potassium excretion in the postobstructed
kidney. Because all these are functions of the collecting tubule,
we postulated that defective collecting tubule transport was a
major feature of urinary tract obstruction of short duration. For
reasons I will discuss, we concluded that a failure to generate a
negative potential difference in the collecting tubule was the
mechanism responsible for the defect.
Amiloride. We next turned our attention to the effects on
urinary acidification of the potassium-sparing diuretic amiloride
[35]. As shown in Table 1, amiloride administration in dogs had
the same effect on urine pH, urine PCO2, and electrolyte
excretion as did unilateral ureteral obstruction. This finding
suggested that the defect in transport induced by urinary tract
obstruction might be the same as that resulting from amiloride
administration. Using amiloride as a probe, we further studied
the effect of amiloride on urinary acidification using the turtle
bladder [35], an experimental analogue of the mammalian
collecting tubule. By exposing this membrane to amiloride, we
hoped to obtain indirect evidence of the nature of the acidifica-
tion defect induced by urinary tract obstruction.
The turtle bladder is believed to contain a proton pump at its
mucosal surface [36, 37]. This pump, which operates in the
absence of sodium transport, secretes hydrogen ion into the
lumen of the bladder. The secretion of a proton results in the
formation of a bicarbonate ion, which passively diffuses across
the serosal membrane of the bladder. The serosal membrane
contains sodium-potassium ATPase, which transports sodium
out of the cell into the serosal medium. This sodium transport
generates a transepithelial gradient such that the mucosal
surface is negative and the serosal surface positive. This
positive potential difference at the serosal surface provides part
of the energy for the passive movement of the bicarbonate out
of the cell. Because a negative electrical potential within the
lumen would favor the secretion of protons, most physiologists
study acidification by the turtle bladder in the "short-circuited"
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state, eliminating the negative potential difference either by the
passage of current or by paralyzing the sodium pump with
ouabain [38]. Acidification continues, albeit at a reduced level,
under these circumstances; its persistence constitutes a major
piece of evidence for an independent, active proton pump.
When amiloride was added to the mucosal solution in the
turtle bladder under short-circuited conditions in a concentra-
tion of l0 M, we noted no effect on hydrogen ion secretion
even though there was a marked fall in potential difference,
measured under open-circuited conditions [35]. Thus, amiloride
has no direct effect on hydrogen ion secretion in this membrane.
This result is not surprising because amiloride blocks sodium
entry into the cell at the mucosal surface. We then repeated the
studies under open-circuited conditions. As has been demon-
strated by others [39], opening the circuit in the turtle bladder
results in an increase in acidification. This phenomenon is
easily explained by the generation of an electrically favorable
gradient for proton secretion. When we added amiloride to the
mucosal solution, hydrogen ion secretion fell to the level
observed during the short-circuited condition. Potential differ-
ence also fell to zero. This result suggested that the effect of
amiloride on acidification was an indirect one attributable to its
effect on transepithelial voltage; this possibility was confirmed
by other studies in which we added amiloride to the turtle
bladder under open-circuited conditions. As in the previous
experiments acidification fell, as did potential difference. At
this point, the potential difference was returned to the control
level by the passage of current. Amiloride remained in the
mucosal solution. Despite the presence of amiloride, return of
the potential difference to its control value completely restored
acidification to the level prevailing prior to the addition of
amiloride. These experiments confirmed that amiloride inhibits
acidification in the turtle bladder and, we infer, in the collecting
tubule, through an indirect effect on sodium transport and
transepithelial voltage.
Lithium. The administration of toxic amounts of lithium
results in another form of experimental DRTA in which acid
excretion is impaired because the generation of a negative
electrical potential within the lumen is inhibited [40, 411.
Animals treated with lithium uniformly develop hyperchioremic
metabolic acidosis if their lithium blood levels exceed 3 mEqi
liter. These animals are not hyperkalemic, however. Further-
more, although they cannot lower the urine pH appropriately
and cannot increase urine PCO2 with bicarbonate loading as
much as normal animals, they do respond normally to the
infusion of either sodium phosphate or sodium sulfate [24, 30].
A probable explanation for these observations is as follows.
Hyperkalemia does not develop because lithium probably inhib-
its transport along the entire nephron, so that its tendency to
reduce potassium secretion in the distal nephron is counterbal-
anced by a reduction in potassium reabsorption more proximal-
ly. Lithium interferes with the generation of a negative voltage
within the lumen, as demonstrated in the turtle bladder [421, by
competing with sodium for transport. The normal acidification
response of the whole kidney to the infusion of either sodium
phosphate or sodium sulfate likely results from increased distal
delivery of sodium; this increase reestablishes normal sodium
transport in the distal nephron.
These observations suggested that DRTA might develop in
humans through a similar mechanism [43]. That is to say, the
Table 2. Features of voltage-dependent distal renal tubular acidosis
I. Sodium wastage
2. Normal or increased plasma aldosterone
3. Hyperkalemia
4. Hyperchtoremic metabolic acidosis
5. Abnormally high urine pH during acidemia
6. Decreased U-B PCO2 in alkaline urine
7. Abnormal response to sulfate or phosphate infusion
proton pump might be intact, but overall acidification might be
reduced as a consequence of impaired sodium transport some-
where in the distal nephron, presumably the cortical collecting
tubule. Impaired sodium transport at this site would result in a
reduced transepithelial potential difference, which secondarily
would reduce acidification. The features of such a defect are
summarized in Table 2. A patient with voltage-dependent RTA
with a tendency to waste sodium would have a normal or
increased plasma aldosterone level and would have hyperkale-
mia in addition to metabolic acidosis. The urine pH would be
inappropriately high for the degree of acidemia, and the re-
sponse to acidifying stimuli abnormal.
Back-leak of acid
The only form of impaired distal acidification that can be
attributed with reasonable certainty to the back-leak of acid is
that seen following the administration of the antifungal antibiot-
ic amphotericin B [43, 44]. This defect has proved difficult to
study in intact animals because animals tend to develop renal
failure before they manifest complete DRTA. Accordingly, our
understanding of this defect is largely based on studies in the
turtle bladder [45, 46]. In this membrane, amphotericin induces
a single defect, that is, an inability to maintain a steep pH
gradient between the serosal and mucosal sides of the mem-
brane. Assuming that proton secretion is intact and acid back-
diffusion increased, amphotericin-treated subjects with im-
paired distal acidification should have low urine PCO2 during
bicarbonate loading. The ability to lower the urine pH during
systemic acidosis should likewise be impaired. The response to
either sodium phosphate or sodium sulfate administration
should be normal owing to the integrity of the proton pump and
the trapping of acid in the lumen as acid phosphate or secondary
to an increase in potential difference.
There is an additional way that a gradient defect could lead to
impaired urinary acidification. Rather than back-diffusion of
acid from tubular urine to blood, it is at least theoretically
possible for bicarbonate to "back-diffuse" from blood to the
tubular urine [28]. Acidification would be decreased by this
phenomenon although the urine PCO2 during bicarbonate load-
ing would not be suppressed. Bicarbonate back-leak would be
associated with either a normal or increased urine PCO2 during
such a procedure, owing to the direct addition of bicarbonate to
an aqueous medium.
Aldosrerone deficiency
Aldosterone deficiency in animals, induced by adrenalecto-
my with selective replacement of pure glucocorticoid hormone,
results in hyperkalemic metabolic acidosis. The ability of these
aldosterone-deficient animals to lower the urine pH in response
to acidemia is intact [47, 481. This finding agrees with the
studies in the turtle bladder that show that aldosterone affects
the conductance of the membrane for protons but does not
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affect the proton driving force; that is, the ability to generate pH
gradients is maintained [49, 50]. Furthermore, the ability to
raise the urine PCO2 in response to either bicarbonate or
phosphate loading is normal in aldosterone-deficient animals
[26, 47]. Similarly, the ability to lower the urine pH in response
to sulfate infusion is intact [47]. Ammonium and potassium
excretion in response to sulfate infusion, however, is reduced
as compared to normals [471. Thus the acidosis in this disorder
seems best explained as the consequence of impaired ammoni-
um excretion which, in turn, is likely the result of both
aldosterone deficiency and its accompanying hyperkalemia.
Clinical distal renal tabular acidosis
Clinical DRTA can be classified under five major categories
according to the underlying abnormality in distal acidification.
In my discussion, I will weave together the clinical features and
the relevant experimental underpinning of these disorders.
Voltage-dependent DRTA
Urinary tract obstruction. Since the prototypic animal model
of a voltage-dependent acidification defect is obstructive uropa-
thy, as I discussed earlier, it seemed logical to see whether this
disorder was present in patients with urinary tract obstruction.
We found a sizable number of patients with hyperkalemic
metabolic acidosis in association with a variety of types of
obstructive uropathy [31]. Fractional excretion of potassium at
any given level of GFR was considerably lower than that
observed in patients with similar degrees of renal insufficiency
who were not hyperkalemic. Thus, the hyperkalemia was at
least partly of renal origin.
The majority of these patients, however, clearly had low
levels of circulating aldosterone. It was thus possible that the
hyperkalemic metabolic acidosis was the result of aldosterone
deficiency and that the obstructive uropathy was just coinciden-
tal. To investigate this possibility, urinary acidification was
measured during either spontaneous or induced acidemia. Nu-
merous studies in animals and humans have demonstrated that,
although overall urinary acidification is reduced in mineralocor-
ticoid deficiency, the ability to lower the urine pH is retained
[26, 31, 47, 48, 51, 52]. Therefore, the finding of hyperkalemic
metabolic acidosis, aldosterone deficiency, and an inappropri-
ately high urine pH would indicate the presence of at least two
disorders, Our patients with obstructive uropathy segregated
into three distinct groups. The patients who did not have
aldosterone deficiency all were unable to lower their urine pH
below 5.5 during acidemia. Some of the patients wth aldoster-
one deficiency also failed to lower the urine pH appropriately
and thus exposed the presence of two distinct disorders,
aldosterone deficiency and hyperkalemic DRTA. The remain-
ing patients with aldosterone deficiency lowered the urine pH
below 5.5 and were considered to have pure aldosterone
deficiency. As a further test for the presence of true DRTA
(defined as the inability to lower urine pH below 5.5), sodium
sulfate was infused in all patients who were unable to lower the
urine pH during acidemia. Despite the potent acidifying stimu-
lus of this maneuver, these patients still were unable to lower
the urine pH below 5.5. Thus, it is clear that obstructive
uropathy is associated with acquired DRTA. In sharp contradis-
tinction to the original form of DRTA described by Albright and
coworkers [3], this disorder is accompanied by hyperkalemia
rather than hypokalemia.
Hemoglobin S. Other disorders associated with this type of
DRTA are those syndromes that share the presence of hemoglo-
bin 5 [53]. The functional pattern of disturbance noted in these
patients is similar to that just described for patients with
obstructive uropathy. Some of these patients have pure aldos-
terone deficiency, whereas others have aldosterone deficiency
superimposed on hyperkalemic RTA. Fractional potassium
excretion is abnormal for the prevailing GFR. All these patients
studied by us, save one with volume contraction, had chronic
renal insufficiency [53]. Earlier studies had demonstrated an
impairment in potassium excretory capacity in patients with
hemoglobin 5 [54]. These patients, however, did not have
hyperkalernia or metabolic acidosis; they also did not have
renal insufficiency. Thus, tubular defects are relatively common
in patients with hemoglobin 5, but they are expressed fully only
when renal insufficiency develops.
Lithium. As yet there are no reports of metabolic acidosis in
patients treated with lithium for affective disorders. We studied
a large number of patients taking lithium for varying periods of
time [12]. None of these patients had either an abnormal serum
potassium level or metabolic acidosis. All were able to lower
pH appropriately following the administration of ammonium
chloride. Urinary concentrating capacity, reduced in patients
who had taken lithium for protracted periods, was relatively
normal in those who had received the drug for shorter periods.
All patients, however, failed to raise the urine PCO2 during
bicarbonate loading. Nonetheless, they did respond normally to
sodium phosphate infusion. We infer from these data that these
patients had a mild acidification defect that was uncovered only
by this experimental manipulation. We suggested that the
definition of incomplete DRTA should be expanded to include
those patients in whom the urine PCO2 does not rise appropri-
ately following sodium bicarbonate administration. This ex-
panded definition does not require that such patients be unable
to lower the urine pH normally. Using such a definition, all
patients receiving lithium appear to have incomplete DRTA.
The clinical importance of this finding awaits further elabora-
tion. Whether overt metabolic acidosis will develop in these
patients with longer exposure to lithium is not known. It is
reasonable to expect that, should another stress be added to the
acid excretory system, metabolic acidosis indeed can occur on
the background of lithium therapy.
Aldosterone deficiency
Over the past few years the syndrome of isolated hypoaldos-
teronism first described by Hudson et al [55], has been recog-
nized frequently [51, 52, 56—59]. A common feature of this
disorder is hyperchloremic metabolic acidosis. The defect in
urinary acidification in these patients does not result from
impaired proximal bicarbonate reabsorption. Because aldoster-
one exerts its renal effect in the collecting tubule, the hyper-
chloremic acidosis in this disorder has been attributed to a
defect in distal nephron function. This type of defect (hyperka-
lemic hyperchloremic DRTA) is often called type-IV RTA [51].
In our view, this term lacks precision because patients with
aldosterone resistance and voltage-dependent DRTA have simi-
lar features [56]. For this reason, we favor the terms aldoster-
one deficiency, aldosterone resistance, and hyperkalemic
DRTA. These terms identify the primary defect involved;
further, this precise definition has important therapeutic impli-
cations and suggests the appropriate therapy.
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Patients with aldosterone deficiency lower urine pH in a
fashion similar to normal subjects. The urine is appropriately
acidic both during systemic acidosis [26, 31, 51, 52] and during
sodium sulfate loading [26]. The urine PCO2 also increases
appropriately both during bicarbonate [47] and phosphate load-
ing [26]. Why aldosterone deficiency does not impair distal
acidification but does result in systemic acidosis is not clear.
Although inhibitory effects of aldosterone deficiency and hyper-
kalemia on urinary ammonia formation have been proposed [48,
51, 561, experimental animals with aldosterone deficiency can
increase urinary ammonium excretion normally, at least on an
acute basis [47]. A decrease in GFR might be a major factor [51,
52, 56—59]. A combination of reduced GFR and aldosterone
deficiency might be required to produce the acidosis; the
adaptive increase in ammonium excretion per remaining neph-
ton mass (that is, an increase in ammonium excretion corrected
for GFR) characteristic of renal insufficiency [60] is lacking in
such patients [53]. Hyperkalemia also exerts a direct depressive
effect on urinary ammonium excretion [58, 61]. Finally, the
effects of hyperkalemia and aldosterone deficiency on ammonia
production might be additive [53].
Aldosterone resistance
The features of renal tubular acidosis due to aldosterone
resistance are similar to those of aldosterone deficiency, except
that blood aldosterone concentration is normal or elevated in
the former. Aldosterone resistance can be differentiated from
hyperkalemic DRTA; patients with hyperkalemic DRTA cannot
lower urine pH during acidosis, whereas patients with aldoster-
one resistance can decrease urine pH during acidemia.
The clinical picture that best illustrates aldosterone resist-
ance is the form described in children [62, 63]. One of the major
manifestations of this disorder is sodium wastage that is well in
excess of that occurring with aldosterone deficiency [64, 65].
Another form of hyperkalemic hyperchioremic acidosis unas-
sociated with salt wastage has been described [66—69]. In one
patient, mineralocorticoid administration failed to increase po-
tassium excretion even when coupled with intravenous infusion
of sodium chloride [69]. Infusion of sodium sulfate resulted in a
normal increase in urinary potassium excretion, however. It has
been proposed that the basic cause of the defect might be the
patient's inability to generate a negative potential difference in
the lumen of the distal nephron as a result of increased
permeability of the distal nephron to chloride, that is, a 'chlo-
ride shunt" [69]. This defect is associated with a normal
acidification response to systemic acidosis or sulfate adminis-
tration [69]. It is likely that these patients would raise urinary
PCO2 normally if they were infused with either bicarbonate or
phosphate, but none has been tested.
In this regard, the syndrome resembles a form of voltage-
dependent DRTA that responds normally to phosphate and
sulfate administration [26]. It differs from that syndrome in that
patients with a "chloride shunt" can lower urine pH normally
during acidosis [69]. Furthermore, as a result of enhanced
sodium chloride reabsorption, low-renin hypertension is a main
feature of a "chloride shunt" [69]. This mechanism might
explain the association between hypertension and hyperkalemic
acidosis [66—69].
Patients whose aldosterone levels are normal or elevated in
the presence of DRTA, hyperkalemia, and a urine pH below 5.5
still can have aldosterone deficiency. It could be argued that
these patients' aldosterone levels are relatively low when their
hyperkalemia is taken into account. Studies on the effects of
chronic mineralocorticoid administration are needed to deter-
mine which of these patients have aldosterone deficiency and
which are resistant to aldosterone.
Acquired normokalemic DRTA
If acquired DRTA develops because of an abnormality linked
directly to acidification, such as failure of the proton pump or
loss of the tubular membranes' capacity to maintain large pH
gradients between tubular urine and blood, hyperkalemia
should not develop [28]. Hypokalemia might develop eventual-
ly, depending on the interrelationship among distal sodium
delivery, circulating aldosterone levels, and the prevailing
GFR. Patients with this type of disorder are not hyperkalemic
and cannot lower urine pH below 5.5 during acidemia [26].
Furthermore, they do not raise the urine PCO2 appropriately
when challenged with sodium phosphate. It is tempting to
speculate that these patients have pure failure of the proton
pump in the collecting tubule. We hypothesized that if the
acidification defect were due to passive back-diffusion of acid
rather than to proton pump failure, such patients would respond
normally to phosphate or sulfate administration, because the
proton pump would be intact [41]. The presence of sulfate or
phosphate in the tubule would retard the backflux of acid,
permitting a normal response.
The only example of such a back-diffusion or gradient type of
disorder definitively known to exist is that secondary to the
administration of amphotericin B [43—45]. Thus far, patients
with DRTA secondary to this agent have not been systematical-
ly studied, either with phosphate or sulfate administration.
Until such studies become available, the distinction between
these two disorders must remain hypothetical.
Another form of acquired normokalemic DRTA is associated
with chronic transplant rejection [25]. Whereas aldosterone
deficiency can be superimposed on this disorder and in turn
cause hyperkalemia, in its pure form the defect is characterized
by normokalemia, an inability to lower urine pH despite the
presence of hyperchloremic metabolic acidosis, and an abnor-
mal response to phosphate administration. These findings sug-
gest failure of the proton pump. This type of DRTA can be the
first manifestation of chronic rejection.
Rate-dependent DRTA
We recently described 4 patients, only one of whom had
metabolic acidosis at the time of study, in whom the only
abnormality of urinary acidification was an inability to raise
urine PCO2 during bicarbonate infusion [13]. According to the
expanded definition I just offered, 3 of these patients have
incomplete DRTA, whereas the fourth has complete DRTA.
Because the only abnormality in these patients is an inability to
raise urine PCO2, and because urine PCO2 during bicarbonate
loading is thought to reflect the rate rather than the force of the
proton pump in the distal nephron, we postulated that these
patients had a rate-dependent defect, In other words, proton
secretion was slowed but not eliminated. In the presence of an
acidifying stimulus such as systemic acidemia or phosphate
administration, acid excretion could be provoked to a "nor-
mal" level. Our formulation is that these patients have an early
form of one of the other defects in distal acidification just
described. Prolonged observation of these patients is needed to
settle this issue. Furthermore, both possibilities might be cor-
Fig. 1. The use of sodium sulfate to
distinguish 'classic" DRTA from voltage-
dependent DRTA. The thin lines represent a
normal subject; the dotted lines, a patient with
hyperkalemic DRTA; and the bold line, a
patient with classic DRTA. Reprinted by
permission of Grune & Stratton (ref. 56).
rect. Some patients with this type of abnormality might have a
rate-dependent defect, whereas others might initially present
with this pattern and later manifest the typical pattern of one of
the forms of DRTA I have described.
Evaluation ofthe patient with DRTA
The general principles behind our approach to patients with
DRTA are shown in Figure 1 [56]. Patients with most forms of
DRTA do not lower the urine pH appropriately when chal-
lenged with sodium sulfate. But potassium excretion rises
normally in patients with "classic" DRTA, whereas patients
with voltage-dependent DRTA fail to exhibit a normal increase
in urine potassium.
Table 3 summarizes the clinical approach to the classification
of RTA [70]. Patients should first be divided into two groups
according to the level of serum potassium, the first group
consisting of those with normal or low serum potassium, and
the second comprising patients with hyperkalemia. The first
group can be subdivided into two additional groups, those who
retain the ability to lower urine pH below 5.5 during acidemia
and those who lack such ability. Proximal RTA must be
excluded in both groups. Isolated proximal RTA is extraordi-
narily rare. When proximal RTA develops, it almost invariably
occurs as part of the Fanconi syndrome [32]. Thus, the pres-
ence of aminoaciduria, renal glucosuria, phosphaturia, and
uricosuria suggests its presence. The diagnosis can be clarified
by the studying of bicarbonate reabsorption. This can be done
by measuring fractional bicarbonate excretion when the serum
bicarbonate concentration exceeds 20 mEq/liter. Under such
conditions, fractional bicarbonate excretion is less than 5% in
patients with DRTA, and it usually exceeds 15% in patients
with proximal RTA [32]. When the diagnosis of proximal RTA
has been excluded, DRTA can be diagnosed in the patients
whose urine pH is greater than 5.5. Patients who maintain the
ability to acidify the urine during acidemia should be challenged
with intravenous sodium bicarbonate. If these patients have a
rate-dependent defect, then the ability to raise urine PCO2
during this procedure will be lost, and the diagnosis of DRTA is
established.
The second group of patients, those with acidosis associated
Low Normal or high Look for specific
plasma cortisol aldosterone
resistance
cause (i.e.,
obstructive
with hyperkalemia, should likewise be divided into two sub-
types, those with urine pH below 5.5 and those with urine pH
above this value. In the former group, plasma aldosterone
concentration should be measured. If plasma aldosterone is low
and plasma cortisol is normal, the diagnosis of selective aldos-
terone deficiency is established. The finding of a low plasma
cortisol in association with a low aldosterone value establishes
the diagnosis of adrenal insufficiency. The finding of a normal
or high aldosterone concentration suggests aldosterone resist-
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7.0
6.5
5.0
4.5
Control Na2SO4 Control Na2SO4 Control Na2SO4
Table 3. Clinical approach to the classification of renal tubular
acidosis'
1. Hyperchloremic acidosis with normal or low plasma potassium
Urine pH during acidosis
<5.5 >5.5
Exclude proximal renal
tubular acidosis
Measure ammonium and
titratable acidity
Measure urine PCO2 during
NaHCO3 infusion (i.e., look
for a "rate-dependent"
defect)
Diagnosis of distal renal tubular
acidosis if bicarbonate
excretion is not high
2. Hyperchloremic acidosis with hyperkalemia
Urine pH during acidosis
<5.5 >5.5
Plasma aldosterone Hyperkalemic distal
renal tubular
acidosis
Normal Low
Selective Adrenal
aldosterone insufficiency
deficiency
Adapted with permission of Grune & Stratton (ref. 70).
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ance. In the group of patients with a urine pH greater than 5.5,
the diagnosis of hyperkalemic DRTA is established without
further evaluation. In these patients, one should look for a
specific cause, such as obstructive uropathy.
The patient presented illustrates a combined defect. He
clearly has aldosterone deficiency, as documented by a plasma
aldosterone concentration of 0.9 ng/dl when his plasma potassi-
um was 5.5 mEq/liter. His ratio of plasma aldosterone to plasma
potassium is 0.2. In our laboratory, this ratio normally exceeds
3. Lower values indicate aldosterone deficiency. After volume
contraction with furosemide, plasma aldosterone was only 3.8
ng/dI, and serum potassium was 5.1 mEq/liter. The plasma renin
activity increased normally; therefore this patient has normore-
ninemic hypoaldosteronism. That a second defect is present is
adduced by the urinary pH. Under conditions of both systemic
acidemia and sodium sulfate administration, urine pH was
approximately 5.9. This failure to lower urine pH below 5.5
indicates the presence of true DRTA. Thus, the diagnosis of
aldosterone deficiency and hyperkalemic DRTA is established.
Because the patient failed to conserve sodium despite pro-
longed dietary deprivation in the presence of fludrocortisone
administration, one should suspect that defective sodium reab-
sorption caused the DRTA.
Principles of treatment
In general, the normokalemic forms of DRTA require little
more than small amounts of bicarbonate or equivalent alkali
therapy. Because the distal nephron is charged with the excre-
tion of an average of 100 mEq of acid per day, the maximal
amount of bicarbonate required to treat such a patient is
obviously 100 mEq. In practice, considerably less bicarbonate
usually suffices, since most patients retain the capacity to
excrete some acid.
Patients with hyperkalemic DRTA should first have their
underlying disease treated if one is present and amenable to
therapeutic intervention. The most important example of such a
disease is obstructive uropathy. In general, distal sodium
delivery should be encouraged and can be accomplished by
administrating generous amounts of dietary sodium. Because
these patients usually have renal insufficiency and commonly
have cardiovascular disease, increasing dietary sodium can
result in edema rather than in increased distal sodium delivery.
In such cases, furosemide should be added to the regimen, This
drug has two salutary effects: it encourages distal delivery and,
by rendering the collecting tubule less permeable to chloride,
favors the exchange of sodium for potassium or hydrogen to
whatever extent such reserve remains. Mineralocorticoid thera-
py is sometimes useful in patients with aldosterone deficiency,
although increasing distal delivery often suffices. Patients with
aldosterone deficiency and a tendency to retain salt might
require diuretic therapy (to encourage distal sodium delivery)
with or without steroid treatment. Salt should not be restricted
in these patients. Other forms of treatment, such as potassium-
exchange resins and alkali administration also might be neces-
sary [10, 56, 70].
Questions and answers
DR. NIcoLAos E. MADIAS: How specific is the acidification
response to phosphate or sulfate infusion in identifying the
acidification defect as "secretory," "voltage dependent," or
"permeability dependent?" I would think for example that the
severity of a secretory defect might well influence the response
to these provocative maneuvers. Additionally, the anatomic
locus of the defect might be an important consideration. Cur-
rent evidence suggests that sodium transport augments acidifi-
cation in the cortical collecting duct, but that hydrogen ion
secretion is virtually sodium independent in the medullary
collecting duct. Thus, a secretory defect involving the cortical
collecting duct might be expected to respond to the above
maneuvers; by contrast, no response would be expected if the
defect involves the medullary portion of the collecting duct.
DR. KURTZMAN: You are correct in surmising that the
severity or the "reversibility" of a defect might influence the
response to sulfate or phosphate infusion. Examples of variable
responses with presumably the same underlying defect are the
amiloride [35, 39] and lithium [12, 40—42] models. In the former,
the response is abnormal. In the latter, a normal response
occurs. Both the amiloride and lithium models are thought to be
examples of voltage-dependent defects. The variability in the
response is likely the result of irreversible inhibition of sodium
transport in the amiloride model, and a defect in sodium
transport that can be overcome by increasing distal delivery of
the cation in the lithium model. Also, a "weak" defect could be
overcome by a powerful stimulus such as sulfate infusion and
could produce a normal response.
A secretory defect involving either the cortical or medullary
collecting tubule should yield a similar response. By secretory,
I mean a defect limited to the hydrogen pump. Regardless of
whether the cortical or medullary tubule is involved, the
acidification response to sulfate and phosphate might be abnor-
mal, whereas the handling of potassium with these maneuvers
should be normal.
DR. MICHAEL P. MADAIO (Division of Nephrology, NEMC):
What is your approach to the treatment of patients with voltage-
dependent distal RTA? These individuals often remain hyperka-
lemic despite furosemide therapy.
DR. KURTZMAN: Patients with voltage-dependent defects
should be treated by increasing distal sodium delivery as much
as practicable. Furosemide therapy is helpful, although dietary
salt intake should not be restricted in these individuals. As you
mention, some patients respond poorly to diuretic treatment. In
these individuals, potassium-exchange resins and sodium bicar-
bonate administration usually control acidosis and hyperkale-
mia. Of course, if obstructive uropathy is present it should be
promptly corrected.
DR. JAMES STROM (Acting Chief, Division of Nephrology, St.
Elizabeth's Hospital, Boston): Do you think that the defect in
hereditary distal RTA is proton pump failure?
DR. KURTZMAN: We have no data concerning this entity.
Other groups are using techniques similar to those I described
today to investigate its pathogenesis. My guess is that it will
turn out to be due to proton pump failure.
DR. STROM: How do you then explain the frequent presence
of moderate to severe hypokalemia in these patients?
DR. KURTZMAN: The hypokalemia common in these patients
presents no problem if one postulates failure of the proton
pump. Sodium transport in the cortical collecting tubule should
be intact. Thus, the development of a lumen-negative potential
difference in the collecting tubule will be unaffected by the
presence of this type of distal renal tubular acidosis. Accordingly,
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because protons cannot be secreted effectively, potassium secre-
tion will be favored.
DR. JOHN T. HARRINGTON: Would you comment on the
alleged difference of some 40 mm Hg between urine and blood
PCO2 levels? Given the ready diffusability of carbon dioxide
across biologic membranes, I find it difficult to conceive of such
a difference.
Da. KURTZMAN: The best available current evidence sug-
gests that whereas the urine and systemic blood PCO2 are
markedly different during bicarbonate loading, the tubular urine
PCO2 and vasa recta PCO2 at the same level within the nephron
are not different [18—2 11. If such is the case, the urinary PCO2
itself rather than the urinary minus blood PCO2 value is the
proper measure of urinary acidification [221.
DR. MADIAS: Would you comment on the recently described
short furosemide test for the evaluation of distal acidification?
DR. KURTZMAN: This test was designed by Dr. Daniel Batlle
and independently by Dr. Jose Arruda and associates [71, 72]. It
is based on the fact that furosemide decreases chloride perme-
ability. If such a decrease were to occur in the cortical
collecting tubule, then chloride would be rendered an imper-
meant anion. Increased delivery of sodium chloride to the
cortical collecting tubule under this circumstance would be
equivalent to increased delivery of sodium sulfate. Therefore,
normal individuals should lower urine pH and increase potassi-
um excretion following the administration of furosemide. Thus
far, the response of individuals with acidification defects to this
test has been identical to that observed with sodium sulfate
infusion [71]. A clear advantage of the furosemide test is that it
can be carried out with only an orally administered test agent
[711.
DR. LouIs BRENES (Staff Physician, Internal Medicine,
Clinica Americana, San Jose, Costa Rica): When using the U-B
PCO2 difference as an index of distal urinary acidification, is
there a lot of variation in the results of successive urine
collections?
DR. KURTZMAN: If one waits until the urine pH exceeds 7.8
and then discards the first urine collected (to avoid artifact due
to the mixing of acid and alkaline urine), the urine PCO2 is
remarkably constant in successive urine samples. The variation
encountered in a given individual does not usually exceed 10
mm Hg.
DR. GEETHA NARAYAN (Nephrology Fellow, NEMC): Distal
tubular sodium reabsorption is diminished in aldosterone defi-
ciency. Why is the defect in hydrogen ion secretion not voltage
dependent?
DR. KURTZMAN: That's a good question. I wish I knew the
answer. The administration of amiloride to aldosterone-defi-
cient animals results in the characteristic voltage-dependent
effect seen when the drug is given to normal subjects. Thus, it
would appear that the absence of aldosterone does not decrease
nephron sodium transport sufficiently to prevent the generation
of a voltage favorable for acidification [73].
DR. MADIAS: In the dog with isolated hypoaldosteronism,
suppression of hyperkalemia results in an increment in urine
ammonium excretion but also in an increase in urine pH and a
fall in urine titratable acid excretion. Do patients with hypoal-
dosteronism respond similarly?
DR. KURTZMAN: Systematic studies of the effect of correct-
ing hyperkalemia in patients with isolated hypoaldosteronism
are not available. That the hyperkalemia plays an important
role, however, has been demonstrated in studies showing the
amelioration of metabolic acidosis in patients with isolated
hypoaldosteronism following correction of hyperkalemia; these
studies indicate that both urine pH and ammonium excretion
increase when potassium falls [58, 74].
DR. JERRY MCCAULEY (Division of Nephrology, NEMC):
How much does hyperkalemia per se contribute towards the
defect in hydrogen ion secretion by inhibiting ammoniagenesis?
DR. KURTZMAN: In my view, a decrease in ammoniagenesis
secondary to hyperkalemia is a major factor in the generation of
the metabolic acidosis. It seems unlikely, however, that hyper-
kalemia has any direct effect on hydrogen ion secretion in the
distal nephron.
DR. MADIAS: I am interested in that group of patients you
alluded to that exhibits normal acid-base status, normal bicar-
bonate reabsorptive capacity, normal response to ammonium
chloride loading and phosphate infusion, but a decreased ability
to elevate the U-B PCO2 during bicarbonate loading. In one
sense, this is an "incompletely-incomplete" RTA. How do you
identify these patients?
DR. KURTZMAN: You can find these patients only by having a
high index of suspicion. If you study patients with moderate
degrees of renal insufficiency—that is, those with a serum
creatinine around 3 mg/dl—and significant interstitial renal
disease, you are likely to find some patients with this "rate-
dependent" defect.
DR. BRENES: Is it your contention that these patients are at
risk of becoming acidemic later in time?
DR. KURTZMAN: Only further observation will answer your
question. My guess is that some of these patients will progress
and develop a more overt form of distal renal tubular acidosis.
In others, a clinical expression of their disorder might occur
only when extra stress is placed on the acidification system.
DR. McCAULEY: What about "normal" individuals? Do
minimal defects in acid excretion occur in the general popula-
tion? Is there a genetic variant that has no clinical significance
unless the individual is stressed?
D. KURTZMAN: We have yet to see an individual totally free
of renal disease whose urinary PCO2 response was not normal.
Patients with the rate-dependent defect all have other evidence
of renal disease. Thus, I think the inability to raise the urine
PCO2 in response to bicarbonate infusion is not likely to be a
variant without clinical significance.
DR. MADIAS: If you were to produce bicarbonaturia in these
patients without associated alkalemia—for example, by admin-
istration of acetazolamide—what would their urinary response
be as compared to normals?
DR. KURTZMAN: We haven't done the study you describe, so
I can only speculate. The response of animals to the administra-
tion of acetazolamide seems to be indistinguishable from that
observed following bicarbonate infusion; that is, the urine PCO2
at any one urine bicarbonate concentration is the same with
either maneuver [75J. Accordingly, I suspect that the response
of these patients to acetazolamide would be the same as we
have observed following bicarbonate administration.
DR. MADIAS: Why does nephrocalcinosis appear to be so
much less common in acquired as opposed to hereditary distal
RTA?
DR. KURTZMAN: Two reasons seem likely to explain the
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difference. Patients with the acquired form almost invariably
have renal insufficiency, and thus urinary calcium excretion is
apt to be much lower than that in patients with the hereditary
form. In addition, in acquired distal RTA the acidosis tends not
to be as severe and not to be present for as long an interval.
Thus a smaller liberation of bone calcium would be expected in
the acquired form.
DR. MADAIO: Where do you think the abnormality is in
patients with voltage-dependent RTA? Excluding the patients
who take amiloride, what are the possibilities?
DR. KURTZMAN: I think the patients we have classified as
having distal renal tubular acidosis on the basis of a voltage
defect have decreased sodium transport in the cortical collect-
ing tubule. The reduced rate of sodium transport decreases the
lumen-negative voltage and results in the typical expression of
this disorder. As to the nature of the transport defect, I can only
speculate. An abnormality in sodium transport any place from
the luminal membrane to the serosal membrane could cause this
defect. In other words, multiple transport abnormalities might
have the same clinical expression provided they all result in
reduced sodium transport and lumen-negative voltage.
DR. DAVID CAHAN (Chief, Nephrology Section, Faulkner
Hospital, Boston): What are your thoughts on the role of renin
in the generation of hypoaldosteronism?
DR. KURTZMAN: Most patients with isolated hypoaldosteron-
ism have low plasma renin activity. One can invoke several
explanations to causally relate renin and aldosterone deficien-
cy. Any disorder that impairs the ability to manufacture and
release renin normally would result in decreased levels of
angiotensin II and thus decreased synthesis and release of
aldosterone. This aldosterone deficiency in turn would result in
potassium retention and in hyperkalemia. Hyperkalemia should
then directly stimulate the zona glomerulosa to make aldoster-
one, and a new steady state would eventuate. In view of the
failure of patients with hypoaldosteronism to manufacture
aldosterone despite hyperkalemia, there must be a defect in the
adrenal response to hyperkalemia. This defect could result from
an intrinsic abnormality in the adrenal gland itself, in which
case one would postulate that the syndrome results from
abnormalities in both the kidney and the adrenal. On the other
hand, the response of the adrenal gland to hyperkalemia might
be influenced by the level of circulating angiotensin II. Pratt
demonstrated that captopril treatment in dogs prevented potas-
sium from increasing plasma aldosterone concentration normal-
ly [761. On the other hand, anephric patients can regulate
aldosterone release in response to changes in plasma potassium
concentration [77]. Finally, the association between aldoster-
one deficiency and hyporeninemia might be fortuitous. Aldos-
terone deficiency might develop as a consequence of adrenal
disease but have no clinical expression as long as cardiovascu-
lar and renal function are normal. That is to say, as long as
distal sodium delivery is high, hyperkalemia and metabolic
acidosis probably will not develop even though aldosterone is
present in subnormal amounts. With aging and the development
of cardiovascular renal disease, decreased distal delivery of
sodium could uncover dormant hypoaldosteronism. The same
renal disease that allows clinical expression of the hormone
deficiency also might result in renin deficiency. None of these
possibilities is exclusive. It is quite likely that the syndrome of
isolated hypoaldosteronism has more than one cause.
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